Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Eduard Roussel Clear advanced filters

  • The approval of pembrolizumab as adjuvant immunotherapy for patients with clear cell renal cell carcinoma meeting the KEYNOTE-564 criteria set new standards and recalibrated future research and clinical needs. Yet, clinical decisions are becoming increasingly nuanced. Achieving clarity in this setting requires a cultural shift aimed at balancing evidence and uncertainty. As a community we should consider this tension as an opportunity to improve on value for patients.

    • Riccardo Campi
    • Daniele Amparore
    • Savio Domenico Pandolfo
    Comments & Opinion
    Nature Reviews Urology
    P: 1-3

  • The BIONIKK trial is the first prospective biomarker-driven randomized trial in metastatic clear cell renal cell carcinoma. This trial demonstrates the feasibility of using a transcriptomic biomarker that reflects intrinsic disease biology to optimize treatment efficacy and shows that all patients might not require combination treatment.

    • Eduard Roussel
    • Benoit Beuselinck
    • Maarten Albersen
    News & Views
    Nature Reviews Urology
    Volume: 19, P: 455-456

  • Multiomics and spatial mapping of tumor samples derived from a real-world cohort of patients with advanced renal cell carcinoma, as well as integration of transcriptomics and human leukocyte antigen genotyping data, provides a machine learning-derived signature of response to immune checkpoint blockade.

    • Lisa Kinget
    • Stefan Naulaerts
    • Abhishek D. Garg
    Research
    Nature Medicine
    Volume: 30, P: 1667-1679

  • Known modifiable risk factors for renal cell carcinoma (RCC) include smoking, obesity and hypertension. Moreover, a potential association between other factors such as diet, dyslipidaemia and physical activity with RCC incidence is also starting to be explored. In this Review, the authors describe the most relevant modifiable risk factors for RCC, discussing the potential implications for prevention and screening programmes.

    • Riccardo Campi
    • Giacomo Rebez
    • Maria Carmen Mir
    Reviews
    Nature Reviews Urology
    Volume: 20, P: 669-681

  • Standard-of-care management of renal cell carcinoma (RCC) relies on surgery for low-risk localized disease and systemic treatment for poor-prognosis metastatic tumours, but patients with high-risk localized tumours and with metastatic disease that has a good-to-intermediate prognosis are in a grey area for treatment. In this Review, the authors provide a comprehensive overview of the current knowledge on surgery and systemic treatment in the management of metastatic and localized RCC.

    • Alexandre Ingels
    • Riccardo Campi
    • Alexandre de la Taille
    Reviews
    Nature Reviews Urology
    Volume: 19, P: 391-418